Ken Griffin Travere Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.89 - $15.21 $240,645 - $463,905	30,500 Added 100.0%	61,000 $853,000
Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $27,878 - $43,884	5,300 Added 21.03%	30,500 $250,000
Q1 2024 May 15, 2024	SELL	$7.18 - $9.82 $359,000 - $491,000	-50,000 Reduced 66.49%	25,200 $194,000
Q4 2023 Feb 14, 2024	SELL	$5.44 - $9.5 $275,264 - $480,700	-50,600 Reduced 40.22%	75,200 $676,000
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $748,720 - $1.69 Million	98,000 Added 352.52%	125,800 $1.12 Million
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $136,170 - $201,229	8,900 Added 47.09%	27,800 $427,000
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $178,200 - $228,900	10,000 Added 112.36%	18,900 $425,000
Q4 2022 Feb 14, 2023	SELL	$18.47 - $26.14 $768,352 - $1.09 Million	-41,600 Reduced 82.38%	8,900 $187,000
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $861,416 - $1.08 Million	37,600 Added 291.47%	50,500 $1.24 Million

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.